Emerging Therapies for Osteoporosis
Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abalopara...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722395/ https://www.ncbi.nlm.nih.gov/pubmed/26354487 http://dx.doi.org/10.3803/EnM.2015.30.4.429 |
_version_ | 1782411359813632000 |
---|---|
author | McClung, Michael R. |
author_facet | McClung, Michael R. |
author_sort | McClung, Michael R. |
collection | PubMed |
description | Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity like teriparatide. Recent data from the phase 3 fracture prevention trial demonstrate that this agent is effective in reducing fracture risk. Inhibiting cathepsin K reduces bone resorption without decreasing the numbers or activity of osteoclasts, thereby preserving or promoting osteoblast function. Progressive increases in bone mineral density (BMD) have been observed over 5 years. Early data suggest that odanacatib effectively reduces fracture risk. Lastly, inhibiting sclerostin with humanized antibodies promotes rapid, substantial but transient increases in bone formation while inhibiting bone resorption. Marked increases in BMD have been observed in phase 2 studies. Fracture prevention studies are underway. The new therapies with novel and unique mechanisms of action may, alone or in combination, provide more effective treatment options for our patients. |
format | Online Article Text |
id | pubmed-4722395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Korean Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-47223952016-01-27 Emerging Therapies for Osteoporosis McClung, Michael R. Endocrinol Metab (Seoul) Review Article Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity like teriparatide. Recent data from the phase 3 fracture prevention trial demonstrate that this agent is effective in reducing fracture risk. Inhibiting cathepsin K reduces bone resorption without decreasing the numbers or activity of osteoclasts, thereby preserving or promoting osteoblast function. Progressive increases in bone mineral density (BMD) have been observed over 5 years. Early data suggest that odanacatib effectively reduces fracture risk. Lastly, inhibiting sclerostin with humanized antibodies promotes rapid, substantial but transient increases in bone formation while inhibiting bone resorption. Marked increases in BMD have been observed in phase 2 studies. Fracture prevention studies are underway. The new therapies with novel and unique mechanisms of action may, alone or in combination, provide more effective treatment options for our patients. Korean Endocrine Society 2015-12 2015-12-31 /pmc/articles/PMC4722395/ /pubmed/26354487 http://dx.doi.org/10.3803/EnM.2015.30.4.429 Text en Copyright © 2015 Korean Endocrine Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article McClung, Michael R. Emerging Therapies for Osteoporosis |
title | Emerging Therapies for Osteoporosis |
title_full | Emerging Therapies for Osteoporosis |
title_fullStr | Emerging Therapies for Osteoporosis |
title_full_unstemmed | Emerging Therapies for Osteoporosis |
title_short | Emerging Therapies for Osteoporosis |
title_sort | emerging therapies for osteoporosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722395/ https://www.ncbi.nlm.nih.gov/pubmed/26354487 http://dx.doi.org/10.3803/EnM.2015.30.4.429 |
work_keys_str_mv | AT mcclungmichaelr emergingtherapiesforosteoporosis |